Sunday, September 20, 2026
GPT-6 is here (with critical security risks)
OpenAI just dropped GPT-6 Astra claiming it's the most intelligent model yet—though it apparently comes with 'critical-level cybersecurity risks' (yikes), while Apollo is scrambling to nearly double its SoftBank credit line to $9B just to keep funding OpenAI. Meanwhile, Ted Cruz wants to fast-track a bipartisan AI safety bill this month, and Anthropic is busy merging Cowork back into Claude while partnering with Novo Nordisk on drug discovery. So we've got the most powerful AI ever built with critical security holes and billions more pouring in—should we maybe pass that safety bill first?
Top Stories
Semafor
Senate lawmakers are making progress on bipartisan AI safety legislation targeting immediate risks like model approvals and harm alerts, with committee Chair Ted Cruz expressing hope for a markup vote before midterm elections, though significant political and industry hurdles remain.
Bloomberg
Apollo is in talks to increase its loan facility to SoftBank from $5.4B to $9B to finance the Japanese conglomerate's OpenAI investments, signaling massive capital flows into leading AI companies and the critical role of alternative financing in the AI race.
Anthropic
Anthropic is consolidating its Cowork feature into the main Claude interface and launching Docs and Slides capabilities in beta, allowing the AI to autonomously handle complex multi-format projects within a single conversation without users needing to choose between different tools.
OpenAI
OpenAI's GPT-6 Astra represents a major leap in AI capabilities with near-perfect benchmark scores and advanced computer use abilities, but its breakthrough cybersecurity skills—including discovering zero-day exploits—have necessitated unprecedented safeguards and restricted access for defensive security work.
Novo Nordisk
Novo Nordisk is partnering with Anthropic to use Claude Science and frontier AI models for drug discovery and software engineering, accelerating R&D timelines as part of its ambition to become the world's most AI-driven healthcare company.
Keep Reading
Industry Voices
Dario Amodei
Co-founder and CEO at Anthropic
Posts detailed technical breakdowns of AI safety research and shares Anthropic's thinking on scaling laws before they become industry consensus.
Mike Doustdar
President and CEO at Novo Nordisk
Offers insights on how AI is transforming drug discovery and clinical trials in diabetes and obesity treatments at the world's leading metabolic disease company.
Enjoyed this issue?
Get daily AI intel delivered to your inbox. No fluff, just the stories that matter.